CliffBio
biologic

Bizengri

zenocutuzumab-zbco

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyMerus NV

Drug detail

Brand nameBizengri
Active ingredientzenocutuzumab-zbco
Strength375MG/18.75ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.